Lyra Therapeutics, INC. (LYRA) — SEC Filings

Overview

Lyra Therapeutics, INC. (LYRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 17, 2026: Lyra Therapeutics, Inc. filed an 8-K on April 17, 2026, to report the termination of a material definitive agreement. The filing indicates that this termination occurred on April 13, 2026. No specific details about the agreement or the counterparty were provided in the filing.

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 4 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Lyra Therapeutics, INC. is neutral.

Filing Type Overview

Lyra Therapeutics, INC. (LYRA) has filed 19 8-K, 6 10-Q, 1 S-1, 1 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13D/A, 5 SC 13G/A, 1 8-K/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• Lyra Therapeutics Terminates Material Agreement — 8-K · Apr 17, 2026 Risk: medium
  Lyra Therapeutics, Inc. filed an 8-K on April 17, 2026, to report the termination of a material definitive agreement. The filing indicates that this termination
• Lyra Therapeutics Terminates Material Agreement — 8-K · Apr 10, 2026 Risk: medium
  Lyra Therapeutics, Inc. filed an 8-K on April 10, 2026, to report the termination of a material definitive agreement. The filing does not specify the agreement
• Lyra's Losses Narrow Amidst R&D Cuts, Going Concern Doubts Persist — 10-Q · Nov 12, 2025 Risk: high
  Lyra Therapeutics, Inc. (LYRA) reported a net loss of $5.98 million for the three months ended September 30, 2025, a significant improvement from the $11.87 mil
• Lyra Therapeutics Files 8-K — 8-K · Sep 4, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting other events and financial statements. The company, formerly known as Arsenal Medical, Inc.
• Lyra Therapeutics Faces Nasdaq Delisting Warning — 8-K · Aug 22, 2025 Risk: high
  Lyra Therapeutics, Inc. announced on August 20, 2025, that it received a notification from Nasdaq regarding its failure to meet the minimum bid price requiremen
• Lyra Therapeutics Navigates Restructuring Amidst Zero Revenue — 10-Q · Aug 12, 2025 Risk: high
  Lyra Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss f
• Lyra Therapeutics Director Departs, Officer Compensation Noted — 8-K · Aug 1, 2025 Risk: low
  Lyra Therapeutics, Inc. announced on August 1, 2025, the departure of Dr. David L. Brown from its Board of Directors. The company also reported on compensatory
• Lyra Therapeutics Files S-1 for Continuous Offering, Signaling Capital Raise — S-1 · Jul 22, 2025 Risk: medium
  Lyra Therapeutics, Inc. filed an S-1 registration statement on July 22, 2025, for a proposed sale of securities on a delayed or continuous basis, indicating a p
• Lyra Therapeutics Announces Material Definitive Agreement — 8-K · Jun 27, 2025 Risk: medium
  Lyra Therapeutics, Inc. announced on June 26, 2025, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equ
• Lyra Therapeutics Merges with HealthBeacon Subsidiary, Delists from Nasdaq — 8-K · Jun 23, 2025 Risk: medium
  On June 13, 2025, Lyra Therapeutics, Inc. announced the closing of its previously disclosed merger with a subsidiary of HealthBeacon Ltd. The transaction was ap
• Lyra Therapeutics Files 8-K — 8-K · Jun 9, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting other events and financial statements. The company, formerly known as Arsenal Medical, Inc., is
• Lyra Therapeutics Files 8-K with Corporate Updates — 8-K · Jun 2, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting an amendment to its articles of incorporation, a Regulation FD disclosure, and other events. The
• AtriCure to Acquire Lyra Therapeutics for $1.1B — 8-K · May 19, 2025 Risk: medium
  Lyra Therapeutics, Inc. announced on May 14, 2025, that it has entered into a definitive agreement to be acquired by AtriCure, Inc. for approximately $1.1 billi
• Lyra Therapeutics Files Proxy Materials — DEFA14A · May 9, 2025 Risk: low
  Lyra Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on May 9, 2025. This filing relates to the company's proxy materials, which are
• Lyra Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  Lyra Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial position and operations, including details on c
• Lyra Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 4, 2025 Risk: medium
  Lyra Therapeutics, Inc. filed its definitive proxy statement on April 4, 2025, for its annual meeting of stockholders. The filing details information regarding
• Lyra Therapeutics Files 2024 10-K — 10-K · Mar 13, 2025 Risk: low
  Lyra Therapeutics, Inc. filed its 2024 10-K on March 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Arsenal Med
• Lyra Therapeutics Files 8-K — 8-K · Jan 10, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on January 10, 2025, to report current information. The filing primarily concerns financial statements and exhibits, as wel
• Perceptive Advisors Adjusts Lyra Therapeutics Stake — SC 13D/A · Dec 16, 2024 Risk: medium
  Perceptive Advisors LLC, along with its affiliates Perceptive Life Sciences Master Fund, Ltd. and Perceptive LS (A), LLC, has amended its Schedule 13D filing re
• Lyra Therapeutics Appoints New Directors, Adjusts Executive Pay — 8-K · Dec 13, 2024 Risk: medium
  Lyra Therapeutics, Inc. announced on December 12, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company ele
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Lyra Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Lyra Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations, incl
• Perceptive Advisors Adjusts Lyra Therapeutics Stake — SC 13D/A · Aug 15, 2024 Risk: medium
  Perceptive Advisors LLC, along with affiliated entities Perceptive Life Sciences Master Fund, Ltd. and Perceptive LS (A), LLC, has amended their Schedule 13D fi
• Lyra Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Lyra Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial activities, including details related to its "
• Lyra Therapeutics Faces Nasdaq Delisting Notice — 8-K · Jul 23, 2024 Risk: high
  Lyra Therapeutics, Inc. announced on July 19, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The com
• Lyra Therapeutics Files 8-K with Corporate Updates — 8-K · Jun 18, 2024 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on June 18, 2024, reporting events that occurred on June 13, 2024. The filing indicates changes to the company's articles o
• Lyra Therapeutics Files 8-K Amendment on Disposal Costs — 8-K/A · Jun 7, 2024 Risk: medium
  Lyra Therapeutics, Inc. filed an amendment (8-K/A) on June 7, 2024, to its Form 8-K dated May 16, 2024. This amendment pertains to costs associated with exit or
• Lyra Therapeutics Directors Depart, Costs Disclosed — 8-K · May 21, 2024 Risk: medium
  Lyra Therapeutics, Inc. announced on May 16, 2024, the departure of two directors, Dr. David Epstein and Dr. Robert Langer, effective immediately. The company a
• Lyra Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 30, 2024 Risk: medium
  Lyra Therapeutics, Inc. (LYRA) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Lyra Therapeutics, Inc. filed a 10-Q report for the period ending
• Lyra Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
  Lyra Therapeutics, Inc. (LYRA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Lyra Therapeutics, Inc. will hold its 2024 Annual Meeting of St
• Lyra Therapeutics Appoints New CMO, Director — 8-K · Apr 19, 2024 Risk: medium
  Lyra Therapeutics, Inc. announced on April 15, 2024, the appointment of Dr. Jeffrey L. Meckler as Chief Medical Officer and the election of Ms. Jennifer M. McNe
• Lyra Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 22, 2024 Risk: low
  Lyra Therapeutics, Inc. (LYRA) filed a Annual Report (10-K) with the SEC on March 22, 2024. Lyra Therapeutics, Inc. filed its annual report on Form 10-K for the
• Lyra Therapeutics Files 8-K on Financials — 8-K · Mar 21, 2024 Risk: low
  On March 21, 2024, Lyra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as we
• Lyra Therapeutics Appoints New Chief Medical Officer — 8-K · Mar 1, 2024 Risk: low
  Lyra Therapeutics, Inc. announced the appointment of Dr. Marc D. G. de Beer as Chief Medical Officer, effective February 26, 2024. Dr. de Beer brings extensive
• Perceptive Advisors Amends Lyra Therapeutics Stake — SC 13D/A · Feb 14, 2024 Risk: medium
  Perceptive Advisors LLC, along with Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd., and Perceptive LS (A), LLC, filed an SC 13D/A (Amendment No. 3)
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• Lyra Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — 8-K · Jan 8, 2024
  Lyra Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its registration on The Nasdaq Global Market unde

Risk Profile

Risk Assessment: Of LYRA's 34 recent filings, 4 were flagged as high-risk, 18 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Lyra Therapeutics, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $25,000
• Net Income: -$5.98M
• EPS: -$3.38
• Cash Position: $22.06M

Key Executives

• Dr. David L. Brown
• Maria Palasis, Ph.D.
• Peter N. Handrinos, Esq.
• Wesley C. Holmes, Esq.
• Joseph Edelman
• Dr. Jonathan M. Rothberg
• Mr. David E. R. Johnson
• Ms. Marie-Louise de la Chapelle
• Mr. Michael J. Wilson
• Dr. David Epstein
• Dr. Robert Langer
• Dr. Jeffrey L. Meckler
• Ms. Jennifer M. McNeely
• Marc D. G. de Beer

Industry Context

The biotechnology industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Lyra Therapeutics rely heavily on clinical trial success and securing substantial funding to bring novel therapies to market. The competitive landscape is intense, with many companies vying for breakthroughs in areas like respiratory diseases.

Top Tags

sec-filing (5) · financials (5) · Biotechnology (4) · 10-Q (4) · delisting (3) · SEC Filing (3) · filing (3) · corporate-governance (3) · ownership-change (3) · Lyra Therapeutics (3)

Key Numbers

• CIK Number: 0001327273 — Identifier for Lyra Therapeutics, Inc.
• SEC Accession Number: 0001193125-26-160421 — Unique identifier for this specific filing.
• Net Loss (9 months): $21.97M — Significantly reduced from $82.46M in prior year, reflecting cost cuts.
• Cash and Cash Equivalents: $22.06M — Decreased from $40.58M at Dec 31, 2024, highlighting liquidity concerns.
• R&D Expenses (9 months): $14.03M — Down from $37.40M in prior year, due to cost reduction and trial failure.
• Employees Reduced: 87 — Impacted by reduction in force in May-June 2024, affecting operational capacity.
• Collaboration Revenue (9 months): $391K — Decreased from $1.33M, indicating reduced external funding.
• Total Stockholders' Deficit: $4.33M — Shifted from $11.59M equity at Dec 31, 2024, indicating negative equity.
• Common Shares Outstanding: 1,774,882 — As of November 7, 2025, reflecting recent share activity.
• Net Loss Per Share (Q3): $3.38 — Improved from $9.07 in Q3 2024, but still a significant loss.
• Commission File Number: 001-39273 — SEC identifier for Lyra Therapeutics
• IRS Employer Identification No.: 84-1700838 — Tax identification for Lyra Therapeutics
• Compliance Period: 180 — Days the company has to regain compliance with Nasdaq's minimum bid price rule.
• Accumulated Deficit: $307.3M — Increased as of June 30, 2025, indicating significant historical losses.
• Revenue: $0 — No revenue for the three and six months ended June 30, 2025, consistent with pre-commercial stage.

Related Companies

ATRC

Frequently Asked Questions